Lion TCR specializes in the development of T cell receptor (TCR)-T cell therapy, particularly targeting Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and other viral infections. Their proprietary therapy utilizes the patient's own immune system to recognize and eliminate HBV-expressing tumor cells, which is crucial given that HBV is a leading cause of HCC, especially in Asia. The company boasts the largest patented TCR library globally, which encompasses HBV-specific TCRs that can address approximately 80% of the patient population across various HLA types. This extensive library enhances the potential for personalized treatment options tailored to individual patients' immune profiles.

The clinical workflow for their lead product, LioCyx-M, involves a streamlined process compliant with current good manufacturing practices (cGMP). This includes leukapheresis to isolate the patient's white blood cells, followed by the expansion and activation of T cells in a state-of-the-art facility. Genetic material encoding the HBV-specific TCR is then introduced into these activated T cells, enabling them to target and destroy HBV-infected or cancerous cells. The therapy has demonstrated promising clinical safety and efficacy, with studies indicating a significant increase in survival time for patients compared to standard treatments. Lion TCR is also exploring the application of their TCR technology for other solid tumors, indicating a broader potential impact in the field of cancer immunotherapy.

Singapore

Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.

Lion TCR

Company Details